Cardioprotective Effect of Losartan Alone or in Combination with Remote Ischemic Preconditioning on the Biochemical Changes Induced by Ischemic/Reperfusion Injury in a Mutual Prospective Study with a Clinical and Experimental Animal Arm
Journal Title: Heart Research – Open Journal - Year 2017, Vol 4, Issue 3
Abstract
Background and Aims: Losartan is an angiotensin receptor II antagonist used clinically to reduce blood pressure and treat hypertension or hypertrophic cardiomyopathy. It is also proposed to suppress cardiac injury following reperfusion. We evaluated the potential effect of Losartan alone and in combination with remote ischemic preconditioning (RIPC), an established treatment, on the biochemical changes induced by ischemic/reperfusion injury (I/R) in both humans and rabbits. Methods: Thirty consecutive patients undergoing elective percutaneous coronary intervention (PCI) were divided into three groups (10 each): group 1 (control group without any preconditioning), group 2 (patients who were maintained on losartan (50-100 mg /day) for one month before PCI), group 3 (similar to group 2 but PCI was preceded by RIPC). On the other hand, sixty adult male New Zealand white rabbits were divided into 6 groups (10 each): group I (control), group II (sham), group III (I/R as 30 min ischemia followed by 120 min reperfusion), group IV (regular losartan 20 mg/kg for 40 days orally followed by I/R), group V (I/R preceded by RIPC) and group VI (similar to groups IV but I/R was preceded by RIPC). Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric oxide (NO), troponin I (cTnI), creatine kinase MB (CK-MB) and C-reactive protein (CRP) were measured in blood for all study groups. Results: Clinical and experimental parts showed that groups with RIPC combined with losartan pretreatment enhanced cardioprotective effects of RIPC against I/R injury as evidenced by significant reduction (p<0.001) in the levels of IL-6 and cTnI; also the level of NO was significantly (p<0. 0.001) increased compared with other groups. However, this effect was not significant regarding the level of TNF-α, CK-MB nor CRP. Conclusions: Pretreatment with losartan enhances the cardioprotective effects of RIPC in ischemic reperfusion injury
Authors and Affiliations
Ayman K. M. Hassan
Keywords
Related Articles
- EP ID EP557964
- DOI 10.17140/HROJ-4-142
- Views 135
- Downloads 0
Carcinoid Heart Disease and Review of Literature
Carcinoid Heart Disease (CHD) is one of the rare causes of acquired valvular heart disease. CHD develops as a systemic manifestation of metastatic neuroendocrine tumors (NETs). When these tumors metastasize to the liver,...
Short-term Cardio-Vascular Risk Score Changes in Type 2 Diabetic Patients on Empaglifozin: A Real-Life Clinical Experience
Objective: The aim of the study was to test both efficacy and safety of empaglifozin in type 2 diabetic out patients followed-up within a single institution. Materials and Methods: One hundred seventy-eight consecutive p...
Effects of Iterative Reconstruction on the Diagnostic Assessment of Coronary Calcium Scores
Coronary Artery Calcium (CAC) score is a widely used indicator to determine disease severity and predict the risk of severe cardiac events. However, radiation dose associated with coronary CT scanning for CAC scoring rai...
Non-Pharmacological Interventions in Refractory Angina
Refractory angina (RA) is defined by intractable cardiac chest pain despite standard medical therapy and revascularisation. Symptoms are associated with significant morbidity and compromised quality of life (QoL). Variou...
Dry Eye Post Surgery Update
A number of studies have mentioned high incidence of asymptomatic dry eye syndrome before cataract surgery and more specifically refractive surgery with Excimer Láser. Ocular surgeries play an important role that can tri...